Haptogen’s strategy rewarded

23 March 2007: Haptogen has triumphed once again at a major conference for the life sciences sector.

Representatives from biotech companies from across the UK took part in an event at the BIA Thistle Bioscience Forum 2007 where each had 15 minutes to ‘showcase’ their business to a panel of UK expert investors and advisers.

It was the confident pitch delivered by Professor Andy Porter, co-founder and CTO of Haptogen, on the continued development of the company’s corporate strategy that secured the top Rising Star Award.

Professor Porter described the strategic development of the company, which has a focus on groundbreaking research into new treatments for inflammation and infectious diseases.

He outlined how Haptogen were now focusing on the development of its research into a strong therapeutic antibody pipeline which would see products being tested in the clinic from 2009.

Haptogen proved once again the success of its current business model based on generating revenue through leveraging its technology and expertise in antibody generation. This recognition by an independent panel of experts supports the approach which continues to deliver strong revenue growth and industry interest. This latter point was demonstrated by the conclusion of 5 major collaborative deals with established international companies in the last 2 months.

Jim Reid, CEO of Haptogen said: “This prize gives recognition to our courageous decision to continue to progress from a technology and service driven company to a company committed to developing novel medicines for the treatment of diseases which affected hundreds of millions of people worldwide.
We are currently discussing various financial options to fast-track these exciting developments’.

Professor Porter and Jim Reid won the title Ernst and Young UK Entrepreneur of the Year in the Science and Technology Category in 2005. In November that year Haptogen was named as a ‘Rising Star’ in Deloitte’s technology awards. Furthermore, last February The Herald newspaper included Haptogen in its list of Top 10 new Scottish businesses.
www.haptogen.com

Ends
 

High resolution image is available from Richard Kent, Kapler Communications richard@kapleronline.com.
Please quote reference HAP/JOB/024

About Haptogen

Haptogen is a fast growing biopharmaceutical company developing human monoclonal antibody therapeutics that meets the challenges of life threatening conditions in inflammation and infectious diseases. Through application of its unique Haptomics®. approach, Haptogen has developed an early stage product pipeline with two products progressing into clinical trial by 2009.

At the same time, the company collaborates with partners to raise antibodies to conventional and more challenging targets, or license its proprietary DBDxTM technology for in-house mAb generation

Press contact: Richard Kent, Kapler Communications Ltd
Tel: +44 (0)1480 471117
E-mail: richard@kapleronline.com

Haptogen contact: Dr Georg Buchner
mobile: +44 (0) 7989596847
Tel: +44 (0) 1224555889
Fax: +44 (0) 1224559614
E-mail: georg.buchner@haptogen.com